Abeona Therapeutics (NASDAQ:ABEO) Shares Down 5.5%

Abeona Therapeutics Inc (NASDAQ:ABEO)’s share price was down 5.5% during trading on Tuesday . The stock traded as low as $3.97 and last traded at $3.99, approximately 716,707 shares traded hands during mid-day trading. An increase of 47% from the average daily volume of 487,382 shares. The stock had previously closed at $4.22.

Several equities analysts have commented on ABEO shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $29.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, May 14th. Zacks Investment Research lowered shares of Exponent from a “buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright set a $55.00 price target on shares of Acer Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 28th. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Finally, BidaskClub upgraded shares of ZIOPHARM Oncology from a “buy” rating to a “strong-buy” rating in a research note on Monday, June 17th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $24.60.

The company has a market cap of $196.16 million, a P/E ratio of -3.35 and a beta of 1.96. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.35. The business’s 50 day moving average is $4.93.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08). Abeona Therapeutics had a negative return on equity of 45.58% and a negative net margin of 960.91%. On average, analysts predict that Abeona Therapeutics Inc will post -1.6 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its position in shares of Abeona Therapeutics by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 341,206 shares of the biopharmaceutical company’s stock worth $2,436,000 after acquiring an additional 6,826 shares during the last quarter. Barclays PLC grew its position in shares of Abeona Therapeutics by 184.9% during the fourth quarter. Barclays PLC now owns 62,885 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 40,811 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Abeona Therapeutics by 37.5% during the first quarter. SG Americas Securities LLC now owns 31,243 shares of the biopharmaceutical company’s stock worth $230,000 after acquiring an additional 8,523 shares during the last quarter. Fosun International Ltd grew its position in shares of Abeona Therapeutics by 37.6% during the first quarter. Fosun International Ltd now owns 98,900 shares of the biopharmaceutical company’s stock worth $719,000 after acquiring an additional 27,000 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY grew its position in shares of Abeona Therapeutics by 247.2% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,194 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 7,258 shares during the last quarter. Institutional investors and hedge funds own 63.61% of the company’s stock.

About Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading: Overbought

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.